HU 308

Pricing Availability   Qty
Cat.No. 3088 - HU 308 | C27H42O3 | CAS No. 256934-39-1
Description: Potent and selective CB2 agonist
Chemical Name: 4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-methanol
Purity: ≥98% (HPLC)
Datasheet
Citations (5)
Reviews
Literature

Biological Activity

Potent and selective CB2 receptor agonist (Ki values are 22.7 nM and > 10 μM for CB2 and CB1 receptors respectively, EC50 = 5.57 nM). Displays antiallodynic activity in the rat hindpaw incision model of postoperative pain. Also neuroprotective and improves motor performance in a mouse model of Huntington's Disease.

Licensing Information

Sold under license from Hebrew University of Jerusalem

Technical Data

M. Wt 414.62
Formula C27H42O3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 256934-39-1
PubChem ID 11553430
InChI Key CFMRIVODIXTERW-BDTNDASRSA-N
Smiles CCCCCCC(C)(C)C1=CC(OC)=C([C@]2([H])[C@H](C3)C(C)(C)[C@H]3C(CO)=C2)C(OC)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 41.46 100
ethanol 41.46 100

Preparing Stock Solutions

The following data is based on the product molecular weight 414.62. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.41 mL 12.06 mL 24.12 mL
5 mM 0.48 mL 2.41 mL 4.82 mL
10 mM 0.24 mL 1.21 mL 2.41 mL
50 mM 0.05 mL 0.24 mL 0.48 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

LaBuda et al (2005) Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur.J.Pharmacol. 527 172 PMID: 16316653

Hanus et al (1999) HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc.Natl.Acad.Sci.USA 96 14228 PMID: 10588688

Palazuelos et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132 3152 PMID: 19805493


If you know of a relevant reference for HU 308, please let us know.

View Related Products by Target

View Related Products by Product Action

View all CB2 Receptor Agonists

Keywords: HU 308, HU 308 supplier, Potent, selective, CB2, agonists, cannabinoids, Receptors, HU308, cb2r, huntingtons, disease, 3088, Tocris Bioscience

5 Citations for HU 308

Citations are publications that use Tocris products. Selected citations for HU 308 include:

Gianella-Borradori et al (2015) Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. Bioorg Med Chem 23 241 PMID: 25487422

Sardinha et al (2014) Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Pharmacol Res Perspect 2014 978678 PMID: 24803745

Solbrig et al (2013) Prospects for cannabinoid therapies in viral encephalitis. Proc Natl Acad Sci U S A 1537 273 PMID: 24021420

Presley et al (2015) Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Brain Res 3 e00159 PMID: 26196013

Ke et al (2016) Activation of Cannabinoid Receptor 2 Ameliorates DSS-Induced Colitis through Inhibiting NLRP3 Inflammasome in Macrophages PLoS One 11 e0155076 PMID: 27611972


Do you know of a great paper that uses HU 308 from Tocris? Please let us know.

Reviews for HU 308

There are currently no reviews for this product. Be the first to review HU 308 and earn rewards!

Have you used HU 308?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Cannabinoid Receptor Ligands

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.